Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul;82(1):e13.
doi: 10.1016/j.eururo.2022.03.029. Epub 2022 Mar 28.

Reply to Yu Wei, Yao Zhu, and Dingwei Ye's Letter to the Editor re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022;82:6-11

F Turco  1 , M Smith  2 , A Omlin  3 , S Gillessen  4
Affiliations
Comment

Reply to Yu Wei, Yao Zhu, and Dingwei Ye's Letter to the Editor re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022;82:6-11

F Turco et al. Eur Urol. 2022 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Fabio Turco and Matthew Smith have nothing to disclose. Aurelius Omlin has received institutioanl advisory fees from AstraZeneca, Astellas, Bayer, Janssen, Molecular Partners, MSD, Pfizer, Roche, and Sanofi Aventis; institutional research support from TEVA and Janssen; travel support from Astellas, Bayer, Janssen, and Sanofi Aventis; and institutional speaker bureau fees from Bayer, Astellas, and Janssen. Silke Gillessen has received personal honoraria for participation in advisory boards from Sanofi, Orion, Roche, Amgen, and MSD, and other honoraria from Televisione Svizzera Italiana; has been an invited speaker for ESMO, the Swiss Group for Clinical Cancer Research (SAKK), the Swiss Academy of Multidisciplinary Oncology (SAMO), the Orikata Academy Research Group, and the China Anti-Cancer Association Genitourinary Oncology Committee (CACA-GU); participates in a speaker bureau for Janssen Cilag; has received a travel grant from ProteoMEdiX; has received institutional honoraria for participation in advisory boards from Bayer, Janssen Cilag, Roche, AAA International, Amgen, Menarini Silicon Biosystems, Astellas Pharma, Tolero Pharmaceutcials, MSD, Pfizer, Telixpharma, BMS, and Orion; and holds patent royalties and other intellectual property for a research method for a biomarker (WO2009138392).

Comment on

  • What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
    Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. Turco F, et al. Eur Urol. 2022 Jul;82(1):6-11. doi: 10.1016/j.eururo.2022.02.010. Epub 2022 Feb 17. Eur Urol. 2022. PMID: 35393158 Free PMC article.

References

    1. Turco F, Armstrong A, Attard G, et al. What experts think about prostate cancer management during the COVID-19 pandemic: report from the Advanced Prostate Cancer Manuscript Click here to view linked References Consensus Conference 2021. Eur Urol. 2022;82:6–11. - PMC - PubMed
    1. Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. In press. 10.1056/NEJMoa2119115. - DOI - PMC - PubMed